Fisher Asset Management LLC cut its holdings in Insulet Corporation (NASDAQ:PODD) by 16.6% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 14,140 shares of the medical instruments supplier’s stock after selling 2,823 shares during the quarter. Fisher Asset Management LLC’s holdings in Insulet Corporation were worth $779,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the business. Granite Investment Partners LLC increased its stake in Insulet Corporation by 0.4% in the second quarter. Granite Investment Partners LLC now owns 19,502 shares of the medical instruments supplier’s stock valued at $1,001,000 after purchasing an additional 76 shares during the period. Principal Financial Group Inc. increased its stake in Insulet Corporation by 1.1% in the first quarter. Principal Financial Group Inc. now owns 8,171 shares of the medical instruments supplier’s stock valued at $352,000 after purchasing an additional 92 shares during the period. The Manufacturers Life Insurance Company increased its stake in Insulet Corporation by 0.4% in the second quarter. The Manufacturers Life Insurance Company now owns 44,746 shares of the medical instruments supplier’s stock valued at $2,296,000 after purchasing an additional 198 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its stake in Insulet Corporation by 11.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock valued at $118,000 after purchasing an additional 235 shares during the period. Finally, Legal & General Group Plc increased its stake in Insulet Corporation by 1.9% in the second quarter. Legal & General Group Plc now owns 20,233 shares of the medical instruments supplier’s stock valued at $1,034,000 after purchasing an additional 376 shares during the period.

TRADEMARK VIOLATION WARNING: “Fisher Asset Management LLC Sells 2,823 Shares of Insulet Corporation (PODD)” was published by TheOlympiaReport and is the property of of TheOlympiaReport. If you are accessing this report on another publication, it was illegally copied and reposted in violation of U.S. & international copyright & trademark laws. The original version of this report can be read at https://theolympiareport.com/2017/10/31/fisher-asset-management-llc-sells-2823-shares-of-insulet-corporation-podd.html.

In related news, EVP Charles Alpuche bought 2,500 shares of the stock in a transaction on Wednesday, September 6th. The shares were purchased at an average price of $58.08 per share, with a total value of $145,200.00. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. 2.60% of the stock is currently owned by company insiders.

Shares of Insulet Corporation (PODD) opened at 58.34 on Tuesday. The stock’s market cap is $3.39 billion. The company’s 50-day moving average is $58.71 and its 200-day moving average is $51.04. Insulet Corporation has a 12-month low of $30.69 and a 12-month high of $62.82.

Insulet Corporation (NASDAQ:PODD) last released its earnings results on Thursday, August 3rd. The medical instruments supplier reported ($0.13) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.13). The firm had revenue of $110.00 million for the quarter, compared to analysts’ expectations of $106.23 million. Insulet Corporation had a negative net margin of 7.30% and a negative return on equity of 46.74%. Insulet Corporation’s quarterly revenue was up 26.0% on a year-over-year basis. During the same quarter last year, the company earned ($0.08) EPS. On average, analysts expect that Insulet Corporation will post ($0.51) earnings per share for the current fiscal year.

A number of research firms have commented on PODD. Robert W. Baird set a $65.00 price objective on shares of Insulet Corporation and gave the company a “buy” rating in a research note on Friday, October 13th. Leerink Swann reiterated an “outperform” rating and set a $74.00 price target (up from $65.00) on shares of Insulet Corporation in a research note on Thursday, October 12th. Zacks Investment Research upgraded shares of Insulet Corporation from a “sell” rating to a “hold” rating and set a $68.00 price target on the stock in a research note on Thursday, October 12th. Wedbush reiterated a “buy” rating and set a $65.00 price target (up from $60.00) on shares of Insulet Corporation in a research note on Tuesday, October 10th. Finally, Canaccord Genuity reiterated a “hold” rating and set a $50.00 price target on shares of Insulet Corporation in a research note on Wednesday, September 27th. Eight analysts have rated the stock with a hold rating, nine have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $56.36.

Insulet Corporation Company Profile

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

Institutional Ownership by Quarter for Insulet Corporation (NASDAQ:PODD)

Receive News & Ratings for Insulet Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.